• Home
• About Makaira
• Investment Team
• Partner Resources
• Portfolio Companies
• Submit Your Executive Summary
• Contact Us
• News
  • Cardiosolutions names Dr. Lars Svensson Chief Surgical Officer
  • Five Questions With: Dr. A. Robert Buonnano
  • Knees In Need
  • CE Mark approval for UniCAP knee
  • Spirus Medical Announces 510(k) Clearance from FDA for Expanded Use of Endo-Ease(R) Discovery SB(TM)
  • Cardiosolutions Raises $7 Million for Spacer Technology to Mitigate Mitral Regurgitation
  • STDMed Inc. Brings Forward Fourth Startup, Closes Series A Financing for Cardiosolutions
  • Spirus gets $8.5M Series B for med devices
  • Frost & Sullivan Names Spirus Medical 2007 U.S. Endoscopy Entrepreneurial Company of the Year
  • Spinoff cycle: STD Med builds devices, startups
  • Arthrosurface Raises $10.5 million in 4th Round of Preferred Equity Financing
  • STD Manufacturing Announces Sale Of AngioLink Corporation
  • Medtronic Acquires Angiolink Corporation, Maker Of Wound Closure Device For Vascular Procedures

Cardiosolutions names Dr. Lars Svensson Chief Surgical Officer

Contact: Ronald Murphy V.P. Investor Relations 781-344-0801
             Jon Wilson      C.O.O. 781-344-0801

FOR IMMEDIATE RELEASE

Stoughton, MA - November 19, 2008 - Cardiosolutions, Inc. (www.cardiosolutionsinc.com ) has announced the appointment of Dr. Lars Svensson M.D., Ph.D. to the position of Chief Surgical Officer. Dr. Svensson is currently the Director of the Center for Aortic Surgery and Director of the Marfan Syndrome and Connective Tissue Disorder Clinic in the Department of Thoracic and Cardiovascular Surgery at Cleveland Clinic.

Cardiosolutions Inc. is developing a leading edge technology for mitigating mitral regurgitation, a condition in which the leaflets of the heart's mitral valve do not close correctly, allowing blood to improperly "backflow" from the lower pumping chamber (left ventricle) upward into the smaller upper chamber (left atrium). Debilitating chronic mitral regurgitation affects approximately 6% of women and 3% of men and currently requires open heart surgery for restoration of valve function. The company's technology consists of a simple spacer, or plug, that is delivered to the mitral valve through a catheter inserted into a vein in the patient's leg. This spacer provides a sealing surface for the valve leaflets minimizing the backflow of blood into the left atrium.

Cardiosolutions is now exploring a surgical option in addition to the current percutaneous system for delivering its spacer technology. A surgical option will allow the Company to work with both the cardiac interventionalist, whose expertise involves catheter based therapies, and the cardiothoracic surgeon who is proficient in open chest procedures. The ability to engage physicians from both the interventionalist and surgical disciplines will allow the company to address a much wider patient population. Dr. Svensson will lead the company's new effort in exploring the potential for surgical delivery through a small chest incision of its Mitra-Spacer^TM technology. Dr. Svensson will also work alongside Dr. Thomas Piemonte Chief Medical Officer of Cardiosolutions Inc., in advancing the catheter based delivery system. "Having Dr. Svensson as our Chief Surgical Officer is a tremendous asset for Cardiosolutions" said Jon Wilson, COO of the company. "He has vast experience pioneering new heart valve technologies and his surgical expertise in mini incision, beating heart techniques will be invaluable in introducing Cardiosolutions technology into the surgical arena".

Cardiosolutions, Inc., headquartered in Stoughton, MA, is developing its proprietary Percu-Pro^TM System, a through the skin procedure for delivering a Mitra-Spacer^TM into the heart for mitigating mitral regurgitation. This percutaneous system avoids open heart surgery, a difficult procedure with far greater risk, an extended period of recovery, and significantly greater cost. Cardiosolutions Inc. was incubated and founded in 2006 by STD Med, Inc., a Stoughton-based manufacturer and developer of medical technologies. In addition to Cardiosolutions, other companies that began at STD Med are Angiolink Corporation, Arthrosurface Incorporated, and Spirus Medical, Inc.

For more on Cardiosolutions Inc. visit http://www.cardiosolutionsinc.com

###